The short answer
Kava may add to flurazepam-related drowsiness and next-day impairment. Flurazepam’s long-lived active metabolite means a short timing gap cannot be assumed protective.
What this answer covers
Piper methysticum beverages/extracts; strength varies.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- flurazepam
Flurazepam can impair next-day activities
A human repeated-dose study found impaired driving after flurazepam. The label describes an active metabolite that accumulates and persists, so the effects are not limited to the moment a capsule is taken.
What the supplement evidence adds
Supplement-specific evidence describes drowsiness or cautions about sedative co-use. It does not establish this exact combination’s adverse-event rate.
Preparations and endpoints differ
A different extract, dose or release formulation may behave differently. A study that fails to show sleep benefit does not prove that a product cannot impair alertness or add to a hypnotic’s effects.
Review co-use rather than choosing a gap
Discuss the product with the prescriber and avoid driving while impaired. No exact protective interval is established. Do not adjust flurazepam yourself; slow breathing or inability to wake requires emergency help.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-impairment/co-use review precaution based on exact flurazepam label and supplement effects, not a proven pair rate or protective short interval.
- Exact scope
- Piper methysticum beverages/extracts; strength varies. with Flurazepam4501 IN; oral hydrochloride capsules and active desalkyl metabolite.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed flurazepam
Additive CNS-depressant effects; active desalkyl metabolite accumulates and may persist for days.
How this applies: Exact flurazepam RxCUI 4501 IN, with stated salt/formulation/route bridge.
No named St John’s wort clinical interaction or universal botanical dose rule.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Participants in a repeated-dose driving study.
Residual driving impairment with flurazepam, including later next-day testing; stronger morning effect.
How this applies: Not a supplement-combination trial; dose and study population do not give exact-pair risk.
Not a supplement-combination trial; dose and study population do not give exact-pair risk.
Source 3: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for flurazepam only within the stated preparation and endpoint limits.
Not a direct flurazepam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for flurazepam only within the stated preparation and endpoint limits.
Not a direct flurazepam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Timing & monitoring
Conditional additive-impairment/co-use review precaution based on exact flurazepam label and supplement effects, not a proven pair rate or protective short interval.
- Exact scope
- Piper methysticum beverages/extracts; strength varies. with Flurazepam4501 IN; oral hydrochloride capsules and active desalkyl metabolite.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed flurazepam
Additive CNS-depressant effects; active desalkyl metabolite accumulates and may persist for days.
How this applies: Exact flurazepam RxCUI 4501 IN, with stated salt/formulation/route bridge.
No named St John’s wort clinical interaction or universal botanical dose rule.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Participants in a repeated-dose driving study.
Residual driving impairment with flurazepam, including later next-day testing; stronger morning effect.
How this applies: Not a supplement-combination trial; dose and study population do not give exact-pair risk.
Not a supplement-combination trial; dose and study population do not give exact-pair risk.
Source 3: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for flurazepam only within the stated preparation and endpoint limits.
Not a direct flurazepam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for flurazepam only within the stated preparation and endpoint limits.
Not a direct flurazepam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact flurazepam article with formulation-specific evidence and uncertainty. |
Article revision: 7f462860cfc00797
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.